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2,3-Dihydroxybenzoic acid decarboxylase, the last enzyme in the fungal metabolism of indole to 
catechol, catalyzes the non-oxidative decarboxylation of 2,3-dihydroxybenzoic acid to catechol. Unlike 
most other decarboxylases, this enzyme does not require a cofactor, underlining the importance of active- 
site residues in the reaction mechanism. Earlier studies from this laboratory [Kamath, A. V., Appaji Rao, 
N. & Vaidyanathan, C. S. (1989) Biochem. Biophys. Res. Commun. 165, 20-261, have shown that the 
sulfhydryl agent N-ethylmaleimide (MaWEt) inactivated the enzyme by modifying a single class of cyste- 
ine residues and that this inactivation was prevented in the presence of salicylate, a substrate analogue. 
In the present study, this essential cysteine residue has been identified by specific labelling with ["C]- 
MalNEt using the differential labelling technique. The stoichiometry of incorporation of [I4C]MaWEt was 
approximately onehbunit  of the homotetrameric protein. The peptide bearing this reactive cysteine resi- 
due was isolated by tryptic digestion of the differentially labelled enzyme and subsequent reverse-phase 
chromatography of the peptide mixture. The sequence of the major radioactive peptide that was identified 
to be the active-site peptide, was LLGLAETCK. A search for sequences similar to this active-site peptide 
indicated that this sequence was probably unique to the decarboxylase under study. A partial primary 
structure map constructed from the sequences of peptides derived from enzymic cleavage of the protein 
using endoproteinase Glu-C and trypsin did not share any significant sequence similarity with sequences 
reported in the database, again suggesting the uniqueness of the enzyme. This is the first report on the 
active-site peptide and the partial primary structure of a non-oxidative decarboxylase catalyzing the re- 
moval of a carboxyl group from an aromatic nucleus. 
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2,3-Dihydroxybenzoic acid decarboxylase (DHBD) is the 
last enzyme in the pathway for the dissimilation of indole by 
fungi [ 11. It catalyzes the non-oxidative decarboxylation of 2,3- 
dihydroxybenzoic acid to catechol, as shown below: 
Scheme 1. 
COOH 
2,3- dihyd roxy benzoic acid catechol 
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Abbreviations. DHBD, 2,3-dihydroxybenzoic acid decarboxylase; 
RP, reverse phase ; MalNEt, N-ethylmaleimide. 
Enzymes. 2,3-Dihydroxybenzoic acid decarboxylase (EC 4.1.1.46); 
salicylate hydroxylase (EC 1.14.13.1) ; orotidine 5'-monophosphate de- 
carboxylase (EC 4.1.1.23); 4,5-dihydroxyphthalate decarboxylase (EC 
4.1.1.55). 
Note. The novel amino acid sequences reported in this study have 
been deposited in the SWISS-PROT protein sequence databank and are 
available under accession number P80346. 
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This enzyme does not seem to require the external addition of 
any cofactor for its activity [2-41. Enzymic reactions of this 
kind which involve, apparently, a simple elimination of the 
COO- group from the aromatic nucleus, have been reported for 
substrates such as 4,5-dihydroxyphthalate, gallate, vanillate, 
orsellinate, 2,4-dihydroxybenzoic acid and 2,6-dihydroxyben- 
zoic acid. Although such reactions have been noticed exten- 
sively in microorganisms transforming aromatic compounds, 
they are equally as important in metabolic pathways as in the 
biosynthesis of naphthoquinones [5]. 
Reactions of this kind are designated as non-oxidative decar- 
boxylation reactions, as opposed to the oxidative decarboxyl- 
ation of salicylate catalyzed by salicylate hydroxylase, a flavo- 
protein which effects the decarboxylation by concomitant hy- 
droxylation at the relevant carbon atom [6]. In contrast to the 
well studied reaction of salicylate hydroxylase, mechanistic 
studies on the enzymic basis of non-oxidative decarboxylation 
are not available, primarily due to the lack of purified enzyme 
preparations with the exception of 4,5-dihydroxyphthalate decar- 
boxylase [7] and DHBD [4]. This communication contributes to 
this little known subject by describing the identification of an 
essential cysteine as part of the primary structure of the protein. 
These results, along with the partial primary structure detailed 
for the enzyme, constitute, to our knowledge, the first report on 
the structure and function of a novel non-oxidative aromatic acid 
decarboxylase. 
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EXPERIMENTAL PROCEDURES 
Materials. Ultrapure urea was obtained from Schwarz- 
Mann. HPLC-grade solvents were obtained from Spectrochem 
or E. Merck. Trifluoroacetic acid and all reagents for gas-phase 
sequencing were obtained from Wako Pure Chemical Co. Tokyo, 
Japan. 14C-labeled N-ethylmaleimide (MaWEt ; 7.4 Ci/mol) was 
purchased from Amersham International plc. All other fine 
chemicals, including sequencing-grade proteases, were pur- 
chased from Sigma Chemical Co. Centricon-30 was obtained 
from Amicon (W. R. Grace and Co.). 
Assay of DHBD. The enzyme was assayed by the disappear- 
ance of 2,3-dihydroxybenzoic acid, as described by Kamath et 
al. [4]. Protein was estimated by the method of Lowry et al. [8] 
using bovine serum albumin as the standard. 
Purification of DHBD. Large-scale purification of DHBD 
was effected by substantial modification of the earlier protocol 
described from our laboratory [4]. Briefly, the steps include the 
preparation of a crude extract from mycelia grown in a medium 
containing anthranilate as inducer of the enzyme, ammonium 
sulphate fractionation (0 - 50 % saturation), ion-exchange chro- 
matography on DEAE-Sephacel and affinity chromatography on 
a matrix containing salicylate. The modifications involve the in- 
clusion of protease inhibitors pepstatin (10 pg/ml), leupeptin 
(10 pg/ml), phenylmethanesulfonyl fluoride (1 mM), l,l0-phen- 
anthroline (5 mM) and EDTA (1 mM) during the first three 
steps, salt washes to eliminate non-specific binding on the affin- 
ity matrix and the use of salicylate rather than 2,3-dihydroxyben- 
zoic acid for affinity elution to avoid the formation of the qui- 
none of 2,3-dihydroxybenzoic acid at pH 7.0 of the buffer. The 
preparation was homogeneous as assessed by SDSPAGE, ana- 
lytical ultracentrifugation and N-terminal analysis (unpublished 
results). 
Specific labelling of the active-site cysteine residue. The 
technique of differential labelling [9] was used to modify the 
active-site cysteine residue of DHBD. In the first step, non- 
essential cysteine residues on the enzyme were modified with 
unlabeled MaWEt with the essential cysteine residue at the 
active site protected by salicylate, a substrate analogue and com- 
petitive inhibitor of DHBD [4]. In the next step, salicylate and 
MaWEt were dialyzed out and the essential cysteine residue, 
now free, was labelled using [14C]MaWEt. 
['4C]MaWEt (solution in pentane, 7.4 Ci/mol, 500 pl, 
13.5 mM) was layered over 250 pl water contained in a conical 
tube. The tube was left open in the fume hood and the pentane 
allowed to evaporate (approximately 2 h). The aqueous solution 
of MaWEt thus obtained (27 mM) was frozen at -20°C until 
use. 
Approximately 300 pg (2 nmol) protein in 50 pl 50 mM so- 
dium phosphate, pH 6.8, was incubated with 6 mM salicylate for 
1 h. An incubation time of 10 min was adequate to protect the 
active site. However, experiments described here were part of 
other protection studies not described in this paper, in which the 
incubation time was 1 h. Unlabelled MaWEt was added to the 
reaction mixture at a final concentration of 10 mM to modify 
the non-essential cysteine residues. The reaction was carried out 
for 1 h, after which time the unreacted MaWEt was inactivated 
by the addition of 10 mM 2-mercaptoethanol. The enzyme was 
dialyzed against 50 mM sodium phosphate, pH 6.8, in order to 
remove salicylate and unreacted MaWEt, and concentrated to a 
volume of 50 pl in a Centricon-30 microconcentrator. 
[I4C]MaWEt (27 mM), was added to the enzyme to a final 
concentration of 2 mM. An aliquot (1 pl) of this mixture was 
withdrawn at defined time intervals and assayed for residual en- 
zyme activity. A similar aliquot was simultaneously spotted onto 
a glass-fibre-coated disc. Individual filters containing aliquots 
of the reaction at different time points, were processed by the 
trichloroacetic-acid-precipitation procedure to determine the ex- 
tent of incorporation of ['4C]MaWEt into the protein. For this, 
the filters were first washed extensively in cold 20% mass/vol- 
ume trichloroacetic acid (10 min, five times) to precipitate the 
protein, then successively with acetone, 95 % ethanol and ether 
(10 min, twice each). The filters were air dried and radioactivity 
determined in a toluene-based scintillation fluid. The stoichiom- 
etry of incorporation ([I4C]MaWEt/protein) at each time point 
was calculated from an estimate of the protein spotted onto each 
filter and a specific activity of 7.4 Ci/mol for MaWEt. 
In experiments where the protein was used for subsequent 
peptide mapping, the specific labelling was carried out for 
15 min using 10 mM [14C]MaWEt, at the end of which time the 
enzyme was completely inactive. The enzyme was dialyzed 
against 0.1 M NH,HCO,, pH 8.0, to remove the unreacted 
MaWEt. 
Peptide mapping. The specifically labelled protein (400 pg) 
was digested with freshly prepared tosylamidophenylethyl- 
chloromethane-trypsin at a protease/substrate ratio of 1 : 25 (by 
mass) for a period of 3 h at 37°C in 0.1 M NH,HCO,, pH 8.0, 
containing 1 M urea. The digest was dried and reconstituted in 
100 p16 M guanidine hydrochloride in 0.1 % trifluoroacetic acid. 
Peptides were separated by reverse-phase (RP) HPLC on a C, 
column using procedures described subsequently. Individual 
peaks were collected separately and 20% vol. each peak used 
for measuring radioactivity in 3 ml Aquasol [lo]. Peptides con- 
taining appreciable radioactivity (> 6000 cpm) were rechro- 
matographed on a C,, column as detailed later. Purified peptides 
containing radioactivity were sequenced and the radioactivity as- 
sociated with each cycle of Edman degradation determined by 
measuring the radioactivity of the fractions collected in the frac- 
tion collector of the sequenator, using Aquasol as the scintilla- 
tion fluid. 
Amino acid analysis. In situ performic acid oxidation of the 
protein (700 pmol) and hydrolysis using 6 M HCl in the vapour 
phase for 24 h at 110°C were carried out by established pro- 
cedures. The hydrolysate was dried and the amino acids ana- 
lyzed on the Waters PICOTAG work station [ l l ] .  
Reduction and alkylation of DHBD. DHBD was reduced 
with dithiothreitol and the cysteine residues carboxymethylated 
using iodoacetic acid [12]. Alternately, alkylation was carried 
out using 4-vinylpyridine [ 131. 
Enzymic cleavage of DHBD. Endoproteinuse Glu-C (V8 
protease). Reduced and carboxymethylated protein (2 mg), dis- 
solved in 50 mM NH40Ac, pH 4.2, containing 1 M urea at a 
final concentration of 5 mg/ml, was digested with Glu-C at a 
protease/substrate ratio of 1 : 100 (by mass). The digestion was 
carried out at 37°C for 18 h [14, 151. The digestion mixture was 
acidified to pH 2.0 to stop the reaction. 
Trypsin. A suspension of the reduced and carboxymethylated 
protein (1 mg) in 100 pl 0.1 M NH4HC0,, pH 8.2, containing 
1 M Gdn/HCl was digested with tosylamidophenylethylchloro- 
methane-trypsin at a protease/substrate ratio of 1 : 100 (by mass) 
at 37°C for 24 h with constant stirring [16]. The digestion mix- 
ture included 1 mM Ca2+ as CaCI, to prevent autodigestion [17]. 
Separation of peptides by HPLC. HPLC was performed 
on a Shimadzu LC-6A system (Shimadzu Corporation) using the 
reverse-phase column CLC-C8 (15 cmX4.6 mm, 6 nm pore size 
and 5 pm particle size) for the preliminary separation of peptides 
and CLC-ODS (C,,) column (15 cmX4.6 mm, 6 nm pore size, 
5 pm particle size) for further resolution and purification of pep- 
tides. The solvent system used throughout this study consisted 
of 0.1 % trifluoroacetic acid in water (solvent A) and 0.08% 
trifluoroacetic acid in 70% acetonitrile (solvent B) [18]. 
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The tryptic or V8 digests, at the end of the specified time, 
were centrifuged to remove insoluble material. The soluble frac- 
tion was dried, dissolved in 0.1 % trifluoroacetic acid containing 
6 M  guanidine hydrochloride and subjected to W-HPLC on a 
C, column equilibrated with solvent A. After an initial wash of 
20 min with solvent A, bound peptides were separated using a 
linear gradient of solvents A and B at a rise of 1 % B/min and a 
flow rate of 0.5 ml/min. The absorbance of the eluate was moni- 
tored at 225 nm. 
Each peak fraction of the primary run was collected man- 
ually and constituent peptides resolved further on a CLC-ODS 
column by manipulations of the gradient employing solvents A 
and B. Essentially, the gradient was a shallow rise of 0.5% B/ 
min, unlike the increase of 1 % Blmin for primary runs. 
Nomenclature of peptides. Peptide fractions were labelled 
T or V according to whether or not they were derived from a 
tryptic or Glu-C digest, respectively, and numbered according to 
their order of elution. The label TN was used for peptides from 
the tryptic digest of the MalAEt-labelled protein. 
Sequence determination. Amino acid sequence determina- 
tion of intact protein and peptides was carried out on the auto- 
mated gas-phase protein sequenator, Shimadzu PSQ-1. Samples 
for sequencing were dissolved in 10% formic acid. 
Analysis of sequences. Sequence comparisons were carried 
out at the Bioinformatics Centre, Indian Institute of Science, 
Bangalore, India. The FASTA program [19] was used to identify 
homologies of the peptides sequenced in this study with se- 
quences reported in the SWISS-PROT protein sequence data- 
base (December 1993, release; [20]). 
RESULTS AND DISCUSSION 
Incorporation of MaWEt at the active site of the enzyme. 
Our earlier work on the enzyme indicated that DHBD was inac- 
tivated by MalhEt, a reagent that is specific for cysteine resi- 
dues. The inactivation followed pseudo-first-order kinetics and 
suggested the presence of a single class of essential cysteine 
residues [21]. In this study, we have established the stoichiome- 
try of this modification reaction using the differential labelling 
technique. DHBD that had been modified at the non-essential 
cysteine residues using unlabelled MaWEt in the presence of 
salicylate, retained greater than 80% of the initial activity. Such 
a modified enzyme was inactivated by 2 mM [‘“CIMaWEt in the 
absence of salicylate. There was a direct correlation between the 
loss of activity and the incorporation of labelled MaWEt 
(Fig. 1). At the end of 90 min, when the enzyme had lost 80% 
of the initial activity, the stoichiometric incorporation of 
[I4C]MalNEt was 3 mol/mol protein. This is equivalent to an 
incorporation of 0.75 mol/subunit, since DHBD is a homotetra- 
mer [4]. In a separate experiment, we noted that MaWEt modi- 
fied 9.5 mol cysteine/mol protein in the absence of salicylate 
and 4.2 mol/mol protein in the presence of salicylate. This cor- 
responds to 1.2 mol cysteinelsubunit protected by salicylate. We 
therefore suggest that this represents a single reactive cysteine 
residuelsubunit enzyme. 
The active-site cysteine-containing peptide. To identify the 
essential cysteine residue as part of the primary structure of the 
protein, the differentially labelled protein was digested with 
trypsin and the resulting peptides separated by RP-HPLC on a 
C, column (Fig. 2A). The radioactivity associated with each 
peak was measured (Fig. 2B). Two peaks, TN19 and TN21, each 
with approximately 12000 cpm and 8000 cpm, respectively, 
contained the maximum radioactivity. These peaks were individ- 
ually rechromatographed on a C,, column in order to obtain pure 
20 40 60 80 
Time (rnin) 
Fig.1. Incorporation of [“TIMaWEt at the active site of DHBD. 
DHBD (2 nmol) was modified at the non-essential cysteine residues with 
unlabelled MaWEt by treating the enzyme with MaWEt (10 mM) in the 
presence of salicylate, the substrate analogue. The enzyme was dialyzed 
and inactivated with [‘4C]MaWEt (2 mM). Aliquots, withdrawn at indi- 
cated time intervals were assayed for residual enzyme activity (0) and 
trichloroacetic-acid-precipitable radioactivity. Incorporation (0) was cal- 
culated as [14C]MaWEt/subunit for the tetramenc DHBD from an esti- 
mate of the protein and radioactivity aliquoted at each time point. 
I I  ’ A 
.o 4 
8 2  
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Fig. 2. Peptide mapping of differentially labeled protein. (A) Separa- 
tion of peptides on a C, column. Specifically labelled protein (400 vg) 
was digested with trypsin at a proteasehbstrate ratio of 1 :25 (by mass) 
in 0.1 M NH,HCO,, pH 8.0, containing 1 M urea. Peptides were sepa- 
rated by RP-HPLC on a C, column using a linear gradient of solvent A 
(0.1 % trifluoroacetic acid) and solvent B (0.08 % trifluoroacetic acid in 
70% acetonitrile). The eluate was monitored at 225 nm. (B) Individual 
peaks were monitored for radioactivity by counting 20% of the volume 
of each peak in Aquasol. The total radioactivity in each peak is shown. 
Peaks containing maximum radioactivity, TN19 and TN21, were rechro- 
matographed and sequenced. 
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Fig. 3. Sequencing of peptide TN19. Peptide TN19 was rechromato- 
graphed to purity and sequenced on an automated gas-phase sequencer. 
The total radioactivity of each aliquot from each cycle of degradation, 
which collected in the fraction collector of the sequenator, was deter- 
mined using Aquasol. The radioactivity depicted is the total radioactivity 
in each aliquot. 
radioactive peptides for sequencing. On rechromatography, 
peaks TN19 and TN21 each yielded a single major radioactive 
peptide, the retention times of which were similar. The amount 
of radioactivity recovered in these peaks, 11 500 cpm and 
7000 cpm, respectively, was quantitative, indicating the covalent 
nature of the MaWEt adduct with the peptide. These peptides 
were sequenced and the radioactivity associated with each cycle 
of sequencing estimated. The sequence of both peptides was 
LLGLAETCK, with maximum radioactivity being recovered in 
cycle 8. The data for TN19 is shown in Fig. 3. The elution of 
the same peptide at two different points on the gradient of the 
primary chromatogram could be due to the different nature of 
contaminating peptides present in these primary peptide frac- 
tions, which were eliminated in subsequent rounds of chroma- 
tography. 
The location of cysteine in the eighth position of the peptide 
was identified from the recovery of maximum radioactivity in 
this cycle. Implicit in this argument is the well documented sta- 
bility of the phenylthiohydantoin derivative of the MaWEt-Cys 
adduct to reaction conditions of Edman chemistry and automated 
sequencing [22]. Coinciding with the recovery of radioactivity in 
this cycle, was the occurrence of a distinct phenylthiohydantoin 
derivative formed during this cycle of sequencing. This phenyl- 
thiohydantoin derivative eluted as a doublet rather than a single 
sharp peak. The doublet could be attributed to the presence of 
both diastereomers of the MaWEt-Cys adduct [22, 231. Similar 
doublets have been documented during the sequencing of 
MaWEt-labelled peptides of isocitrate dehydrogenase [24] and 
proteosome [25]. This was also confirmed independently from 
the sequence of the peptide PT13 from the pyridethylated pro- 
tein whose sequence was LLGLAETCK, with pyridethylated 
cysteine eluting in the eighth cycle (data not shown). 
Since a major portion of the radioactivity was detected in 
two peptides which had identical sequences, LLGLAETCK, and 
since the loss of activity was associated with the incorporation of 
label, we suggest that this peptide contains an essential cysteine 
residue and forms part of the active site protected by salicylate. 
Similar studies carried out on the enzyme from A. spergillus 
oryzae also identified an essential cysteine residue that was la- 
belled with [i4C]MaWEt with a stoichiomehy of 0.8 moVmol 
subunit, and the peptide bearing the label was identified as 
LLGLAETCK (data not shown). The identical sequence of this 
peptide in the two enzymes, apart from indicating a similar 
active-site structure, testifies to the functional significance of the 
peptide. Sequence comparison of this peptide with sequences in 
the SWISS-PROT database revealed that there was no sequence, 
reported so far, that was similar to the active-site peptide. 
Table 1. Amino acid composition of DHBD. The amino acid composi- 
tion was determined by the PICOTAG method. The number of amino 
acidshbunit was calculated using a relative molecular mass of 
38000 Da, determined by SDSPAGE, and a mean residue mass of 
110 Da. Cysteine was determined as cysteic acid. Tryptophan was not 
determined. 
Global average Amino acid No. of residues 
A. niger no. residues 
(moll100 mol) 
CYS 5 (1.4) (1.9) 
Asp + Asn 44 (12.7) (10.4) 
Glu + Gln 37 (10.7) (9.4) 
Ser 14 (4.0) (6.8) 
GlY 24 (6.9) (7.2) 
His 10 (2.9) (2.3) 
Ark? 21 (6.1) (5.1) 
Thr 21 (6.1) (5.9) 
Ala 31 (9.0) (7.8) 
Pro 16 (4.6) (5.9) 
Val 20 (5.8) (6.6) 
Met 8 (2.3) (2.3) 
Ile 19 (5 .5)  (5.3) 
Phe 30 (8.7) (3.9) 
Leu 22 (6.4) (9.1) 
LYS 18 (5.2) (5.9) 
TYr 17 (4.9) (3.2) 
Partial primary structure of DHBD. The identification of a 
unique active-site peptide for DHBD prompted us to elucidate 
its primary structure. As a first step, the amino acid composition 
of the protein was determined by the PICOTAG method (Table 
1). A comparison of the amount of each residue with the average 
composition computed for proteins [26] indicated that DHBD 
had a relatively high content of phenylalanine, which was ap- 
proximately twice that of an average protein. Other amino acids, 
however, were present in the same proportions as for the average 
protein. 
The sequencing of reduced and carboxymethylated DHBD 
yielded the following N-terminal sequence : MLGKIALEEA- 
FALPRFEEKTR. The unambiguous identification of a single 
amino acid in each cycle testified to the purity of the prepara- 
tion. 
DHBD was sequenced using protein sequencing methods. 
Enzymic cleavage of DHBD was used to generate peptides for 
sequencing. Endoproteinase Glu-C, noted for its high specificity, 
was used in an Nb+-based buffer in order to limit the specificity 
of the enzyme to glutamate residues. A pH of 4.2 was chosen, 
keeping in mind the easy solubility of the denatured protein at 
acidic rather than alkaline pH. Digestion with endoproteinase 
Glu-C provided the maximum number of purified peptides that 
could be sequenced. A total of 16 peaks (Vl-Vl6) were ob- 
tained on RP-HPLC of the Glu-C digest (Fig. 4). Individual 
rechromatography of these peak fractions on a C,, column gave 
a total of 34 pure peptides. The tryptic digest of reduced and 
carboxymethylated or pyridethylated protein could be separated 
by RP-HPLC into about 41 primary peptide fractions (Fig. 5). 
These were resolved further by chromatography on a C,, col- 
umn. The sequences of some of these were used singly (PT41, 
Table 2) or in conjunction with peptide sequences from the Glu- 
C digest to obtain longer stretches of sequence information. The 
final picture of the sequence information obtained for DHBD is 
indicated in Table 2. 
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Fig. 4. Separation of peptides from the Glu-C digest of DHBD. Pep- 
tides were separated by FW-HPLC on a C, column using the acetonitrile 
solvent system in a gradient application with a rise of 1 % B/min between 
solvent A (0.1% trifluoroacetic acid) and solvent B (0.08% trifluoro- 
acetic acid in 70% acetonitrile). The eluate was monitored at 225 nm 
and individual peaks numbered V1 -V16 were collected separately and 
rechromatographed on a C,, column using the same solvent system with 
a gradient rise of 0.5% Blmin. Inset, the rechromatography of V4 is 
shown as a representative example. AUFS, absorbance units full scale. 
0.32 
0.32 AUFS 
100 
Comparison of the sequences of peptides with other protein 
sequences. An estimate of the similarity of the sequence of a 
protein with the sequence data in databases often provides in- 
sight into the evolutionary relationships of the protein and pro- 
vides clues to its function or possible mechanism of action. A 
recent example is the identification of the cofactor requirement 
for 4-chlorobenzoate dehalogenase from an inspection of the se- 
quence relationships of the enzyme [27]. It was, therefore, of 
interest to determine whether the sequenced stretches of DHBD 
had sequence similarity to the sequences reported in the data- 
base. 
Each of the sequences listed in Table 2 was compared with 
the SWISS-PROT protein sequence database using the software 
FASTA. The 20 best scorers in each search were a random set 
of proteins with no obvious structural or mechanistic similarities 
to DHBD. Furthermore, no single protein was consistently iden- 
tified, even with a low degree of similarity, in these searches. 
The lack of significant similarity of any of the sequences ob- 
tained for DHBD, including the active-site sequence, with any 
other protein, could suggest that the sequence information was 
exclusive to DHBD and could account for the uniqueness of the 
decarboxylation it catalyzes. 
Conclusion. We have earlier proposed a mechanism that ac- 
counts for our evidence for the requirement of essential histi- 
dine, cysteine and tryptophan residues for the DHBD reaction 
[21]. The mechanism invokes an acidhase-catalyzed deprotona- 
tion of the C(2)-OH to form an intermediate quinone. Decarbox- 
ylation is facilitated from this resonance-destabilized intermedi- 
ate. The intermediate is transformed to the product catechol in a 
subsequent reprotonation step. The participation of the histidine 
residue in the first step and a cysteine residue in the last step, 
are probable with tryptophan anchoring the aromatic substrate: 
0 
20 30 40 50 60 70 
Time (min) 
Fig. 5. Separation of peptides from the tryptic digest of DHBD. The 
separation was carried out on a C, column using the acetonitrile solvent 
system with a gradient of 1 % B/min. Each peak was collected manually 
and rechromatographed. 
The unambiguous sequence information covered 292 of the 
expected 345 residues of the protein, although these residues are 
not continuous. A major limitation in obtaining more sequence 
information has been the limited solubility of the denatured pro- 
tein at alkaline pH, the optimal pH value at which most prote- 
ases are active. The complete sequence of this protein can be 
obtained using other strategies for cleavage and separation of 
peptides or by using the sequence information presented here to 
design oligonucleotides for a nucleic-acid-based approach, both 
of which are currently under way in our laboratory. The avail- 
ability of the complete sequence of this unique decarboxylase 
would form the basis of intensive structure/function studies of 
this enzyme. 
Scheme 2. 
n 
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A recent report [28] on the decarboxylation of vanillate carried 
out by resting cells of Rhodotorula in a deuterium-based me- 
dium, seems to support our hypothesis. However, structure/ 
function studies on purified enzyme preparations such as that 
described here would be essential to understand the details of 
such reactions. For example, the extremely hydrophobic nature 
of the active-site peptide reported in this study could play a role 
in shielding the reactive quinone intermediate and prevent un- 
wanted side reactions. 
The sequences of several decarboxylases have been reported 
in the database. All of these decarboxylases, with the exception 
of orotidine 5'-monophosphate decarboxylase [29], catalyze the 
decarboxylation from aliphatic substrates, including amino 
acids. Orotidine 5'-monophosphate too, is a heterocyclic sub- 
strate where the ring nitrogen functions to stabilize the incipient 
carbanion, a key feature of all decarboxylation reactions [30]. 
2,3-Dihydroxybenzoic acid, unlike orotidine 5'-monophosphate, 
is a benzenoid substrate where such decarboxylation strategies 
are not immediately obvious. Against this background of scant 
information on the non-oxidative decarboxylases, the informa- 
tion presented in this paper is the first report of the active-site 
cysteine residue and the partial primary structure of a non-oxida- 
tive decarboxylase catalyzing the decarboxylation from an aro- 
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Table 2. The sequence information of DHBD. Peptides designated Sant. 1 to Sant. 9 were compiled from sequences of Glu-C and tryptic peptides 
by the overlap method. Sant.10. to Sant.19 represent sequences of individual peptides from the tryptic or Glu-C digests, which have not been placed 
in the context of other peptides. TN16 is a minor radioactive peptide from Fig. 2. Sant. 18 is the active-site peptide in Fig. 3 whose sequence was 
confirmed from the sequence of a tryptic peptide PT13. 
Peptide Sequence Description 
_ _ _ _ _ ~  
No. amino acids 
Sant. 1 MLGKIALEEAFALPRFEEKTRWALSFSVDPE 
S a t .  2 IEHADKYGVGYQILSYTAPGVQDIWDPVEAQAGE 
Sant. 3 VGVDRILSIDYPFETFEDAAW 
Sant. 4 LRRDVQTYGFIGALVNDTQRTGPMGNNQEEAYN 
Sant. 5 INDYIAEQIRDKPDRFGAFTLSMHNPQEA 
Sant. 6 GRDNAARLFE 
Sant. 7 RNPTGTIYEK 
Sant. 8 LGAFRDYDAKVKA 
Sant. 9 EITDINKLRIE 
Sant. 10 NASWDIFWQTDTE 
Sant. 11 AQALAVE 
Sant. 12 DADVWFDGAE 
Sant. 13 FYDNA 
Sant. 14 AMQYVIA 
Sant. 15 Y GAK 
Sant. 17 INH/GWFEDR 
Sant. 18 LLGLAETCK 
Sant. 19 WLVGPDLSFAHGVSLHVLGMTVNGVFDR 
Total no. amino acids sequenced 
Sant. 16 QADIYGP/G 
N-terminus 
V11.3 
v2.1 
V7.1 
T38.6 
V1.4 
V1.4 
V 1.7 
TN16 
PT13, active site peptide 
PT41 
_____ 
32 
34 
22 
33 
29 
10 
10 
13 
11 
13 
7 
10 
5 
7 
4 
7 
8 
9 
28 
2921345 
matic nucleus. These studies pave the way for in-depth studies 
to unravel a mechanistically interesting class of reactions. 
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